David R. Brenneman

Partner

David R. Brenneman represents clients primarily in mergers, acquisitions, joint ventures, and civil antitrust litigation. In the merger process, David works on premerger notification under the Hart-Scott-Rodino Act, international merger control, merger investigations, second requests, and compliance with consent orders. David represents pharmaceutical, chemical, and financial services clients before the Federal Trade Commission and US Department of Justice, and he coordinates filings for multimillion- and multibillion-dollar transactions worldwide. David is a member of the Morgan Lewis Committee on Foreign Investment in the United States (CFIUS) working group.

News

6/23/2017 - Morgan Lewis Elects 31 New Partners

6/2/2017 - Morgan Lewis Advises SK Capital Partners in Two Platform Acquisitions that Close on Same Day

4/21/2017 - Morgan Lewis Represents DoubleU Games in Acquisition of DoubleDown Interactive from IGT

3/24/2016 - Morgan Lewis Advises Mercury Systems Inc in $300M Microsemi Businesses Acquisition

11/23/2015 - Morgan Lewis Serves as Lead U.S. Antitrust Counsel to Pfizer in Blockbuster Combination with Allergan

11/6/2015 - Morgan Lewis Represents Eureka Growth Capital and Regent Holding Company in Sale of Creative Co-Op

10/14/2015 - Morgan Lewis Advises Svenska Cellulosa Aktiebolaget in $513M Pending Acquisition

8/3/2015 - Morgan Lewis Advises Foresight Biotherapeutics Inc. in Sale to Shire plc

7/2/2015 - Morgan Lewis Advises Health Net, Inc. in $6.8 Billion Sale to Centene Corporation

2/5/2015 - Morgan Lewis Advises CRH plc on €6.5bn Asset Acquisition from Lafarge and Holcim

View more...